# Integra LifeSciences (IART) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IART
## Company Profile
- Ticker: IART
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: MedTech
## Stock Data
- Close: 13.85 USD
- Market cap: 1219077470.01 USD
- Last updated: 2026-10-13
## Business Overview
### Medical Technology Portfolio
Integra LifeSciences develops medical technologies used in neurosurgery, reconstructive surgery and wound care. Its products support procedures in which tissue protection, repair and regeneration are critical to patient outcomes.
### Neurosurgical Technologies
The company supplies instruments, implants and systems used in neurosurgery and neurocritical care. These products include technologies for dural repair, intracranial pressure management, tissue ablation and precision surgical access.
### Tissue and Wound Reconstruction
Integra’s regenerative-tissue portfolio includes products used for soft-tissue reinforcement, wound closure and surgical reconstruction. SurgiMend is a biologic matrix intended to return to production from the company’s Braintree manufacturing facility.
## Why The Stock Is Moving

As of Oct 13, 2026, IART closed down 0.93% at $13.85. No new same-company headline was identified in the current news window.

## Future Catalysts

- Start of SurgiMend production at the Braintree facility targeted by the end of June 2026.
- Relaunch of SurgiMend expected in the fourth quarter of 2026.

## Recent News
- 2026-10-09 21:22 EST — [Integra Announces Pricing of Senior Secured Notes](https://biopharmsignal.com/news/IART/integra-announces-pricing-of-senior-secured-notes-777221ab) — Source: Integra LifeSciences
- 2026-10-06 12:30 EST — [Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026](https://biopharmsignal.com/news/IART/integra-lifesciences-to-host-third-quarter-2026-financial-results-conference-cal-7fa664b2) — Source: Integra LifeSciences
- 2026-10-02 12:05 EST — [Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance](https://biopharmsignal.com/news/IART/integra-lifesciences-announces-preliminary-third-quarter-results-and-updates-ful-3a4f7bc4) — Source: Integra LifeSciences
- 2026-10-02 12:00 EST — [Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B](https://biopharmsignal.com/news/IART/integra-lifesciences-announces-launch-of-600-million-senior-secured-term-loan-b-644b6be4) — Source: Integra LifeSciences
- 2026-09-29 12:30 EST — [Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry](https://biopharmsignal.com/news/IART/integra-lifesciences-announces-100th-patient-enrolled-in-aera-pediatric-registry-396d83ff) — Source: Integra LifeSciences